Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 5/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680673 | 0.86 | PTGER4 (0.35) | MEN1KMT2AUSP7 | |
| SCHEMBL30538800 | 0.84 | MEN1 (0.32) | MEN1TP53PABPC1KMT2AUSP7 | |
| SCHEMBL29770310 | 0.75 | FGFR1 (0.47) | FGFR1 | |
| SCHEMBL27237114 | 0.75 | LMNA (0.32) | MEN1KMT2A | |
| SCHEMBL30497261 | 0.73 | MEN1 (0.43) | MEN1TP53PABPC1KMT2A | |
| SCHEMBL25405520 | 0.72 | GLP1R (0.41) | — | |
| SCHEMBL29392201 | 0.72 | GLP1R (0.41) | — | |
| SCHEMBL25405514 | 0.72 | GLP1R (0.41) | — | |
| SCHEMBL29924431 | 0.72 | — | — | |
| SCHEMBL30259333 | 0.71 | MKNK2 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119330949-A | Polycyclic compound and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240360109-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4382525-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-117751110-A | Cycloolefin derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023011539-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2022228490-A1 | POLYCYCLIC DERIVATIVE MODULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360109-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CYP51A1, FAR1, CYP46A1 | MEN1 1346/4885TP53 4154/4885PABPC1 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.